D. Brooks

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

A. Maitra, M. Hidalgo, J. Watters, 2011, Clinical Cancer Research.

Abstract A258: The PARP inhibitor niraparib demonstrates synergy with chemotherapy in treatment of patient derived Ewing's sarcoma tumorGraft models.

E. Bruckheimer, K. Wilcoxen, T. Khor, 2013 .

DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study

O. Rosen, S. George, F. Janku, 2016 .